Myopia – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Myopia occurs when the focused image is too close to the eye's retinal photoreceptor layer. Myopia is classified into two types. The simple, less severe conditions are also known as physiological or school myopia, and they occur as a result of the correlative failure of the normal eye's refractive components. It can also be caused by an increase in the curvature of the surface of the cornea or lens and an increase in the axial diameter of the eye. Myopia of up to – 6.0 D is involved. Pathological, degenerative, malignant, or high myopia is a rare form that causes progressive elongation of the globe and accompanying stretching of the scleral wall, resulting in a high refractive error of – 6 D or higher. High myopia frequently causes choroid atrophy and subsequent retinal macular degeneration, resulting in loss of central visual acuity and an increased risk of retinal detachment, glaucoma, and strabismus. High myopia is a significant cause of legal blindness in many developed countries. However, genetic and environmental factors that have been implicated in the etiology of myopia remain to be known.

 

The prevalence of patient pool of myopia varies from 90 MN to 100 MN in the USA, with a male and female ratio of 46% and 54%.

 

The competitive landscape of Myopia includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Myopia across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Myopia Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Myopia – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          NVK-002           Nevakar, Inc.    Phase 3

2          Atropine 0.1% Ophthalmic Solution         Bausch & Lomb Incorporated     Phase 3

3          DE-127 Ophthalmic Solution      Santen Pharmaceutical Co., Ltd.            Phase 2

4          SYD-101           Sydnexis, Inc.   Phase 3

5          EXP039            Canyon City Eyecare     Phase 2

6          SHJ      Sunhawk Vision Biotech, Inc.     Phase 1

7          Pilocarpine Ophthalmic  Eyenovia Inc.    Phase 3

8          EV06 Ophthalmic Solution         Encore Vision, Inc.        Phase 2

9          Pilocarpine Ophthalmic  Glaukos Corporation      Phase 2

10        Aceclidine and Brimonidine        LENZ Therapeutics, Inc Phase 2